FREE SHIPPING ON ORDERS OVER $150

sglt2 inhibitors and glp-1 receptor agonists Combining in Type 2 Diabetes Mellitus: A Scoping Review and Expert Insights for Clinical Practice Utilizing the Nominal Group Technique Renal and urothelial cancer risks

$24.51

Quantity
- +
Description

McGuire DK, Shih WJ, Cosentino F, Charbonnel B, Cherney DZ, Dagogo-Jack S, et al

sglt2 inhibitors and glp-1 receptor agonists Combining in Type 2 Diabetes Mellitus: A Scoping Review and Expert Insights for Clinical Practice Utilizing the Nominal Group Technique Renal and urothelial cancer risks

American Diabetes Associations 77th Scientific Session 2017

sglt2 inhibitors and glp-1 receptor agonists Combining in Type 2 Diabetes Mellitus: A Scoping Review and Expert Insights for Clinical Practice Utilizing the Nominal Group Technique Renal and urothelial cancer risks

These agents are recommended as first-line therapy by the American Diabetes Association and the European Society of Cardiology for patients with diabetes and underlying cardiovascular disease [4, 5]

sglt2 inhibitors and glp-1 receptor agonists Combining in Type 2 Diabetes Mellitus: A Scoping Review and Expert Insights for Clinical Practice Utilizing the Nominal Group Technique Renal and urothelial cancer risks

Actual results vary by individual and treatment plan

sglt2 inhibitors and glp-1 receptor agonists Combining in Type 2 Diabetes Mellitus: A Scoping Review and Expert Insights for Clinical Practice Utilizing the Nominal Group Technique Renal and urothelial cancer risks

SURPASS-CVOT compared once-weekly tirzepatide with dulaglutide in adults with type 2 diabetes and high cardiovascular risk, showing a 9% relative risk reduction in MACE (HR 0.92, 95% CI 0.83 to 1.01)

sglt2 inhibitors and glp-1 receptor agonists Combining in Type 2 Diabetes Mellitus: A Scoping Review and Expert Insights for Clinical Practice Utilizing the Nominal Group Technique Renal and urothelial cancer risks

You may also like

recommand products